Unknown

Dataset Information

0

Preclinical validation of a potent γ-secretase modulator for Alzheimer's disease prevention.


ABSTRACT: A potent γ-secretase modulator (GSM) has been developed to circumvent problems associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary prevention of early-onset familial Alzheimer's disease (EOFAD). Unlike GSIs, GSMs do not inhibit γ-secretase activity but rather allosterically modulate γ-secretase, reducing the net production of Aβ42 and to a lesser extent Aβ40, while concomitantly augmenting production of Aβ38 and Aβ37. This GSM demonstrated robust time- and dose-dependent efficacy in acute, subchronic, and chronic studies across multiple species, including primary and secondary prevention studies in a transgenic mouse model. The GSM displayed a >40-fold safety margin in rats based on a comparison of the systemic exposure (AUC) at the no observed adverse effect level (NOAEL) to the 50% effective AUC or AUCeffective, the systemic exposure required for reducing levels of Aβ42 in rat brain by 50%.

SUBMITTER: Rynearson KD 

PROVIDER: S-EPMC7931646 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7294721 | biostudies-literature
| S-EPMC9076685 | biostudies-literature
| S-EPMC6421538 | biostudies-literature
| S-EPMC4115564 | biostudies-literature
| S-EPMC4647268 | biostudies-literature
| S-EPMC3087138 | biostudies-literature
| S-EPMC2936959 | biostudies-literature
| S-EPMC2740474 | biostudies-literature
| S-EPMC7919141 | biostudies-literature
| S-EPMC6469197 | biostudies-literature